&lt;p&gt;Evaluation of the Characteristics of Asthma in Severe and Extremely Severe COPD&lt;/p&gt;

Chen, Feng-jia; Lin, Guoli; Huang, Xinyan; Liu, Yang-Li; Zeng, Zhimin

doi:10.2147/copd.s225258

Cited by 3 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results revealed significantly higher levels of total IgE in ACOS patients compared with asthmatic patients, which was considered an unexpected finding considering the differences in the treatment drugs. This finding is consistent with the results of Chen et al 15 Another study showed significantly higher concentrations of total IgE in asthma compared with ACOS. 16 Compared with single asthma or single COPD, ACOS is more complex and includes the symptoms of both asthma and COPD.…”

Section: Discussionsupporting

confidence: 93%

<p>Serum IL-8 and VEGFA are Two Promising Diagnostic Biomarkers of Asthma-COPD Overlap Syndrome</p>

Ding¹,

Sun²,

Zhang³

et al. 2020

COPD

View full text Add to dashboard Cite

Background: Asthma-COPD overlap (ACO; previously referred to as asthma-COPD overlap syndrome) is characterized by persistent airflow limitation consistent with COPD, together with several distinguishing features of asthma. Asthma-COPD overlap syndrome is a condition of mixing symptoms of asthma and COPD, because of its complexity, it is difficult to find effective diagnostic markers in clinic. Purpose: Our aims were to detect the expression of serum cytokines in patients with asthma, explore the diagnostic potential of differential serum cytokines in ACOS. Patients and Methods: Ninety asthmatic patients were divided into ACOS group and non-ACOS group according to the major and minor criteria of ACOS, 15 kinds of cytokines including IL-3, IL-4, IL-8, IL-9, IL-13, IL-17A, VEGFA, VEGFC, VEGFD, bFGF, Fit-1 PIGF, Tie-2 were detected by MSD, and IL-27 and TGF-beta were determined by ELISA assay. Results: The serum levels of IL-9, VEGFA and PIGF in patients with ACOS were significantly higher than those in non-ACOS group (P<0.05, respectively), while the level of IL-8 and IL-17A in subjects with ACOS was lower than that in the non-ACOS group (P<0.05, respectively). We analyzed the correlation between several difference factors and FEV1/FVC% in the ACOS group, found VEGFA was negatively correlated with FEV1/FVC %, while IL-8 and IL-17A were positively correlated with FEV1/FVC%. Finally, three correlation factors were analyzed by ROC curve for the occurrence of ACOS. Conclusion: The results suggested that IL-8 was highly sensitive and VEGFA was highly specificity, both of which could be used as biomarkers for the diagnosis of ACOS.

show abstract

Section: Discussionsupporting

confidence: 93%

<p>Serum IL-8 and VEGFA are Two Promising Diagnostic Biomarkers of Asthma-COPD Overlap Syndrome</p>

Ding¹,

Sun²,

Zhang³

et al. 2020

COPD

View full text Add to dashboard Cite

show abstract

“…There are many studies that compared FeNO in COPD subjects with ACO [ 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 ]. Although higher levels of FeNO were observed in ACO patients compared to those with COPD-only, it is still difficult to interpret the results of these studies.…”

Section: Existent Type2 Biomarkers In Copdmentioning

confidence: 99%

“…The prevalence rate of FeNO >25 ppb was 36.9%, those of >35 ppb, >50 ppb were 16.3%, and 5.1%, respectively. Similarly, another recent study reported that, in 178 severe (FEV 1 predicted ≤ 50%) COPD patients, FeNO ≥ 25 ppb was found in 32.9%, and FeNO ≥ 50 ppb was 2.6% [ 113 ].…”

Section: Existent Type2 Biomarkers In Copdmentioning

confidence: 99%

“…Recently, the diversity of airway inflammation in COPD has also attracted attention. Based on the findings that the correlations between FeNO values and blood eosinophil counts in patients with severe and extremely severe COPD were not significant, Chen et al have proposed that FeNO and blood eosinophil counts should be both evaluated in patients with COPD [ 113 ]. The use of composite Type2 biomarkers has been recommended for the definition and diagnosis of ACO in several national and international guidelines [ 149 , 150 ].…”

Section: Existent Type2 Biomarkers In Copdmentioning

confidence: 99%

See 1 more Smart Citation

Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease

Oishi

Matsunaga

Shirai

et al. 2020

JCM

View full text Add to dashboard Cite

Airway inflammation in chronic obstructive pulmonary disease (COPD) is typically thought to be driven by Type1 immune responses, while Type2 inflammation appears to be present in definite proportions in the stable state and during exacerbations. In fact, some COPD patients showed gene expression of Type2 inflammation in the airway, and this subset was associated with the inhaled corticosteroid (ICS) response. Interestingly enough, the relationship between COPD and diseases associated with Type2 inflammation from the perspective of impaired lung development is increasingly highlighted by recent epidemiologic studies on the origin of COPD. Therefore, many researchers have shown an interest in the prevalence and the role of existent Type2 biomarkers such as sputum and blood eosinophils, exhaled nitric oxide fraction, and atopy, not only in asthma but also in COPD. Although the evidence about Type2 biomarkers in COPD is inconsistent and less robust, Type2 biomarkers have shown some potential when analyzing various clinical outcomes or therapeutic response to ICS. In this article, we review the existent and emerging Type2 biomarkers with clinically higher applicability in the management of COPD.

show abstract

Clinical Indicators for Asthma-COPD Overlap: A Systematic Review and Meta-Analysis

Peng¹,

Wang²,

Wu³

et al. 2022

COPD

View full text Add to dashboard Cite

Background Some clinical indicators have been reported to be useful in differentiating asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) from pure asthma/COPD, but the results were inconsistent. This study aims to evaluate the diagnostic value of these indicators for ACO. Methods Databases of PubMed, EMBASE, Ovid and Web of Science were retrieved. Pooled standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated in random-effects models. Results 48 eligible studies were included. The pooled results indicated, compared with pure asthma, ACO patients had lower levels of forced expiratory volume in the first second (FEV 1 )% predicted (pred) (SMD=−1.09, 95% CI −1.3 to −0.87), diffusion lung capacity for carbon monoxide (DLCO)% pred (SMD=−0.83, 95% CI −1.24 to −0.42), fractional exhaled nitric oxide (FeNO) (SMD=−0.23, 95% CI −0.36 to −0.11), and higher levels of induced sputum neutrophil (SMD = 0.51, 95% CI 0.21 to 0.81), circulating YKL-40 (SMD = 0.96, 95% CI 0.27 to 1.64). However, relative to COPD alone, ACO patients had higher levels of FEV 1 % pred (SMD = 0.15, 95% CI 0.05 to 0.26), DLCO% pred (SMD = 0.38, 95% CI 0.16 to 0.6), FeNO (SMD = 0.59, 95% CI 0.40 to 0.78), serum total immunoglobulin (Ig)E (SMD = 0.42, 95% CI 0.1 to 0.75), blood eosinophil (SMD = 0.44, 95% CI 0.29 to 0.59), induced sputum eosinophil (SMD = 0.62, 95% CI 0.42 to 0.83), and lower levels of induced sputum neutrophil (SMD=−0.48, 95% CI −0.7 to −0.27), circulating YKL-40 (SMD=−1.09, 95% CI −1.92 to −0.26). Conclusion Compared with pure asthma/COPD, ACO patients have different levels of FEV 1 % pred, DLCO% pred, FeNO, serum total IgE, blood eosinophil, induced sputum eosinophil/neutrophil, and circulating YKL-40, which could be helpful to establish a clinical diagnosis of ACO.

show abstract

<p>Evaluation of the Characteristics of Asthma in Severe and Extremely Severe COPD</p>

Cited by 3 publications

References 30 publications

<p>Serum IL-8 and VEGFA are Two Promising Diagnostic Biomarkers of Asthma-COPD Overlap Syndrome</p>

<p>Serum IL-8 and VEGFA are Two Promising Diagnostic Biomarkers of Asthma-COPD Overlap Syndrome</p>

Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease

Clinical Indicators for Asthma-COPD Overlap: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About